Drug intelligence / Profile preview

follitropin alfa + lutropin alfa

Development stage
Approved
Lead developer
Merck KGaA
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

**Follitropin alfa + lutropin alfa** is a fixed-dose recombinant gonadotropin combination marketed as **Pergoveris**. It combines recombinant human follicle-stimulating hormone and recombinant human luteinizing hormone in a 2:1 ratio, typically 150 IU follitropin alfa plus 75 IU lutropin alfa per daily dose. The components are produced in genetically engineered Chinese hamster ovary cells. The product is used to stimulate follicular development in adult women with severe luteinizing hormone and follicle-stimulating hormone deficiency, including anovulation associated with gonadotropin deficiency. Follitropin alfa activates follicle-stimulating hormone receptors to support granulosa-cell function and follicular growth, while lutropin alfa activates luteinizing hormone/choriogonadotropin receptors to support theca-cell steroidogenesis, follicular maturation, and ovarian sensitivity to follicle-stimulating hormone. It is administered by daily subcutaneous injection as a solution in a pre-filled pen or as powder and solvent for solution for injection. ([ema.europa.eu](https://www.ema.europa.eu/en/documents/product-information/pergoveris-epar-product-information_en.pdf))

Brand names
Pergoveris
Other names
follitropin alfa/lutropin alfafollitropin alpha + lutropin alphar-hFSH + r-hLHr-hFSH/r-hLHrecombinant human follicle-stimulating hormone + recombinant human luteinizing hormone
02

Targets

FSHR (Follicle-stimulating hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)

Beyond the preview

Go deeper on follitropin alfa + lutropin alfa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on follitropin alfa + lutropin alfa.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call